BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...Pharmaceuticals Ltd. in 2011 to develop epigenetic and cell proliferation assets obtained when Progen bought CellGate Inc....
...professor of oncology at The Johns Hopkins University School of Medicine and former consultant to CellGate...
BioCentury | Jul 6, 2009
Company News

Progen, Global TransBiotech Inc., KAI Pharmaceuticals Inc deal

...Phase II testing for pain. Progen acquired the transporter technology in its 2008 acquisition of CellGate Inc....
BioCentury | Aug 18, 2008
Clinical News

PG11047: Phase I restarted

...47-01-002) trial evaluating PG11047 in combination with various marketed drugs in up to 126 patients. CellGate Inc....
BioCentury | May 19, 2008
Clinical News

PG-11047: Phase I restarted

...restarted a dose-escalation Phase I trial of PG-11047 (formerly CGC-11047) in patients with advanced cancer. CellGate Inc....
BioCentury | Feb 11, 2008
Company News

Cellgate, Progen deal

...Progen acquired CellGate for about US$1.5 million in stock and up to US$19.5 million in milestones...
...up to US$19.5 million in milestones. Progen also will assume up to US$1 million of CellGate's...
...HDAC and lysine-specific demethylase 1 ( LSD1 ) to treat cancer. Burrill LLC advised Progen. CellGate Inc....
BioCentury | Dec 3, 2007
Company News

Novacea management update

...Business: Cancer, Hematology Hired: Edward Schnipper as EVP and CMO, formerly president and CEO of CellGate Inc. WIR...
BioCentury | Jan 29, 2007
Product Development

Back-of-the-eye pipeline

...D) Athenagen Mecamylamine (ATG003) Formulation of mecamylamine, a nicotinic receptor antagonist Wet AMD Ph I Cellgate...
BioCentury | Nov 13, 2006
Clinical News

CGC-11047: Phase I started

...an open-label, dose-escalation, U.S. Phase I trial in 15 patients who will receive CGC-11047 subconjunctivally. Cellgate Inc....
BioCentury | Nov 6, 2006
Clinical News

CGC-11047: Phase II started

...will receive 200 mg of IV CGC-11047 once-weekly for 3 weeks over a 4-week cycle. Cellgate Inc....
BioCentury | Oct 9, 2006
Clinical News

CGC-11047: Phase Ib started

...Basel, Switzerland); and Tarceva erlotinib is from OSI Pharmaceuticals Inc. (OSIP, Melville, N.Y.) and DNA. Cellgate Inc....
Items per page:
1 - 10 of 28
BioCentury | Apr 5, 2012
Targets & Mechanisms

AML takes LSD1

...Pharmaceuticals Ltd. in 2011 to develop epigenetic and cell proliferation assets obtained when Progen bought CellGate Inc....
...professor of oncology at The Johns Hopkins University School of Medicine and former consultant to CellGate...
BioCentury | Jul 6, 2009
Company News

Progen, Global TransBiotech Inc., KAI Pharmaceuticals Inc deal

...Phase II testing for pain. Progen acquired the transporter technology in its 2008 acquisition of CellGate Inc....
BioCentury | Aug 18, 2008
Clinical News

PG11047: Phase I restarted

...47-01-002) trial evaluating PG11047 in combination with various marketed drugs in up to 126 patients. CellGate Inc....
BioCentury | May 19, 2008
Clinical News

PG-11047: Phase I restarted

...restarted a dose-escalation Phase I trial of PG-11047 (formerly CGC-11047) in patients with advanced cancer. CellGate Inc....
BioCentury | Feb 11, 2008
Company News

Cellgate, Progen deal

...Progen acquired CellGate for about US$1.5 million in stock and up to US$19.5 million in milestones...
...up to US$19.5 million in milestones. Progen also will assume up to US$1 million of CellGate's...
...HDAC and lysine-specific demethylase 1 ( LSD1 ) to treat cancer. Burrill LLC advised Progen. CellGate Inc....
BioCentury | Dec 3, 2007
Company News

Novacea management update

...Business: Cancer, Hematology Hired: Edward Schnipper as EVP and CMO, formerly president and CEO of CellGate Inc. WIR...
BioCentury | Jan 29, 2007
Product Development

Back-of-the-eye pipeline

...D) Athenagen Mecamylamine (ATG003) Formulation of mecamylamine, a nicotinic receptor antagonist Wet AMD Ph I Cellgate...
BioCentury | Nov 13, 2006
Clinical News

CGC-11047: Phase I started

...an open-label, dose-escalation, U.S. Phase I trial in 15 patients who will receive CGC-11047 subconjunctivally. Cellgate Inc....
BioCentury | Nov 6, 2006
Clinical News

CGC-11047: Phase II started

...will receive 200 mg of IV CGC-11047 once-weekly for 3 weeks over a 4-week cycle. Cellgate Inc....
BioCentury | Oct 9, 2006
Clinical News

CGC-11047: Phase Ib started

...Basel, Switzerland); and Tarceva erlotinib is from OSI Pharmaceuticals Inc. (OSIP, Melville, N.Y.) and DNA. Cellgate Inc....
Items per page:
1 - 10 of 28